Skip to content

Opening book details…

Can I read The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy on EtoBox?

The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy by Georges Vlastos; Nadeem Q. Mirza; Jeffrey T. Lenert; Kelly K. Hunt; Fred C. Ames; Barry W. Feig; Merrick I. Ross; Aman U. Buzdar; S. Eva Singletary is a Medicine article available to read on EtoBox.

What is The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy about?

## BACKGROUND. Induction chemotherapy (IC) has become the standard of care for locally advanced breast carcinoma, frequently downstaging both the primary tumor and the axilla, and making patients eligible for less invasive surgical procedures. The usefulness of IC in earlier stage operable breast carcinoma is now being considered. ## METHODS. This study involved a subset of 129 patients from a series of 174 with T2-3, N0 -1, M0 or T1, N1, M0 breast carcinoma (Stage IIA, IIB, or IIIA ) who were registered in a prospective IC trial using paclitaxel or a combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The subset included patients who had received no preoperative radiation therapy but had completed 3-5 cycles of induction chemotherapy and had undergone a Level I-II axillary lymph node dissection. The objective was to evaluate the effectiveness of induction chemotherapy with paclitaxel or FAC in downstaging the primary tumor and axillary metastases in these early stage breast carcinoma patients. ## RESULTS. The median initial tumor size was 4 cm (range, 0.6 -10.0); after IC, tumor size was downstaged to 1.6 cm (range, 0.0 -7.0) (P Ͻ 0.0001). Clinical response to IC

Who reads The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Georges Vlastos; Nadeem Q. Mirza; Jeffrey T. Lenert; Kelly K. Hunt; Fred C. Ames; Barry W. Feig; Merrick I. Ross; Aman U. Buzdar; S. Eva Singletary
Publisher
John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)
Published
2000
Language
EN
Field
Medicine (Health Sciences)

More by Georges Vlastos; Nadeem Q. Mirza; Jeffrey T. Lenert; Kelly K. Hunt; Fred C. Ames; Barry W. Feig; Merrick I. Ross; Aman U. Buzdar; S. Eva Singletary

Browse all works by Georges Vlastos; Nadeem Q. Mirza; Jeffrey T. Lenert; Kelly K. Hunt; Fred C. Ames; Barry W. Feig; Merrick I. Ross; Aman U. Buzdar; S. Eva Singletary